FibroBiologics Inc

For the period ended Dec 31, 2023. Filed Feb 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 29, 2024

FBLG$0.92-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Power of Attorney (included in the signature page)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Robert Hoffman
Signature	Title	Date
/s/ Pete O’Heeron	Chairperson and Chief Executive Officer	February 29, 2024
Pete O’Heeron	(Principal Executive Officer)
/s/ Mark Andersen	Chief Financial Officer	February 29, 2024
Mark Andersen	(Principal Financial Officer and Principal Accounting Officer)
/s/ Robert Hoffman	Director	February 29, 2024
/s/ Victoria Niklas	Director	February 29, 2024
Victoria Niklas, M.D.
/s/ Richard Cilento	Director	February 29, 2024
Richard Cilento
/s/ Matthew Link	Director	February 29, 2024
Matthew Link

FIBROBIOLOGICS, INC.

INDEX TO FINANCIAL STATEMENTS

Audited Financial Statements for the Years Ended December 31, 2023 and 2022
Report of Independent Registered Public Accounting Firm	F-1
Balance Sheets as of December 31, 2023 and 2022	F-2
Statements of Operations for the Years Ended December 31, 2023 and 2022	F-3
Statements of Changes in Stockholders’ Equity/(Deficit) for the Years Ended December 31, 2023 and 2022	F-4
Statements of Cash Flows for the Years Ended December 31, 2023 and 2022	F-5
Notes to the Financial Statements	F-6

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.